Pharmaceutical company Roche (SIX:RO) (ROG;OTCQX:RHHBY) reported on Friday the receipt of US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the cobas SARS-CoV-2 Nucleic acid test for use on the cobas Liat System for both symptomatic and asymptomatic individuals.
At the July launch, the company said its cobas SARS-CoV-2 Nucleic acid test will be available in markets accepting the CE mark.
In addition, the company's cobas SARS-CoV-2 singleplex test is the first RT-PCR test that screens within 20 minutes both asymptomatic and symptomatic persons, enabling quick, informed decisions at the point of care. The test is for use at a wide range of point-of-care settings, including but not limited to emergency and primary care, physician offices and screening locations, enabling greater access for patients.
The company added the test offers broad strain coverage of SARS-CoV-2 variants providing reassurance with clinician-care decisions.
Based on the company's PCR technology, the cobas Liat System fully automates the testing process, simplifies workflow and enables healthcare providers to perform molecular testing in a variety of point-of- care settings with speed, reliability and minimal training.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT